In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
Former Energy CIO Examines Evolving Tech Priorities
Ann Dunkin discussed challenges in acquisition that impact how agencies can approach federal technology strategies and efficiencies.
14m listen -
Inside the DOGE Caucus' Fight Against Government Waste
Co-Chair Rep. Pete Sessions discussed the tech strategies to enhance operational efficiency at federal agencies.
17m listen -
HIMSS: AI Revolutionizes Federal Health Services
NTT Data’s Noel Hara shares insights on AI, efficiency and innovation in IT strategy and healthcare outcomes.
8m watch -
NCI Explores AI’s Potential for Cancer Screenings
NCI is researching how AI could improve cancer screenings, access to data and reduce mortality rates.
14m listen